Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

SURMOUNT-2

Eli Lilly · Phase 3 · Completed · Enrollment 938

NCT04657003

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

86.4130.5581.55
≥5%
69.588.6863.43
≥10%
51.782.5741.42
≥15%
33.980.9622.98
≥20%
Show as table
Arm≥5%≥10%≥15%≥20%
10 milligrams (mg) Tirzepatiden/rn/rn/rn/r
15 mg Tirzepatide86.41%69.58%51.78%33.98%
Placebo30.55%8.68%2.57%0.96%
10 mg Tirzepatide81.55%63.43%41.42%22.98%

Not shown

  • 10 milligrams (mg) Tirzepatide: endpoint not reported